Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again-Reference-Cited by-同舟云学术

Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again

Published:2012-07-25 Issue:6 Volume:32 Page:1153-1164
ISSN:0271-9142
Container-title:Journal of Clinical Immunology
language:en
Short-container-title:J Clin Immunol

Author:

Wasserman Richard L.

Publisher

Springer Science and Business Media LLC

Subject

Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s10875-012-9740-x.pdf

Reference83 articles.

1. Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: A working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol. 2010;135(2):255–63.

2. APIIEG. Consensus recommendations for the use of immunoglobulin replacement therapy in immune deficiency.2nd edition 2009. http://www.apiieg.org/files/1/APIIEG%20Consensus%20Recommendations%20Edition%201%20June%202008.pdf . Accessed 10/24/2011.

3. Bruton O. Agammaglobulinemia. Pediatrics. 1952;9(6):722–8.

4. Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—A prospective, multi-national study. J Clin Immunol. 2006;26(2):177–85.

5. Long AA, Denburg JA, Dent PB. Hypogammaglobulinemia: therapeutic rationale. CMAJ. 1987;137(9):793–7.

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biochemical Characterization of Hyaluronate Lyase CpHly8 from an Intestinal Microorganism Clostridium perfringens G1121;Applied Biochemistry and Biotechnology;2024-09-05

2. Long-Term Safety of Facilitated Subcutaneous Immunoglobulin 10% Treatment in US Clinical Practice in Patients with Primary Immunodeficiency Diseases: Results from a Post-Authorization Safety Study;Journal of Clinical Immunology;2024-08-19

3. Insights into Patient Experiences with Facilitated Subcutaneous Immunoglobulin Therapy in Primary Immune Deficiency: A Prospective Observational Cohort;Journal of Clinical Immunology;2024-08-05

4. Protecting children and adults with primary antibody deficiencies against common and emergent pathogens and non-infectious complications;Clinical and Experimental Immunology;2024-07-16

5. Subcutaneous immunoglobulins (SCIG) for chronic inflammatory demyelinating polyneuropathy (CIDP): A comprehensive systematic review of clinical studies and meta-analysis;Neurological Sciences;2024-06-28